HAART联合扶正抗毒丸对气虚质无症状期HIV感染者免疫功能的作用

目的?探讨高效抗反转录病毒疗法（HAART）联合扶正抗毒丸对气虚质无症状期人类免疫缺陷病毒（HIV）感染者免疫功能的作用。方法?将符合纳入标准的气虚质无症状期HIV感染者根据自愿原则分为HAART组、扶正抗毒丸组，HAART组给予替诺福韦（每次300 mg）+拉米夫定（每次300 mg）+依非韦伦（每次600 mg），每日1次；扶正抗毒丸组在HAART组用药的基础上加服扶正抗毒丸（每次6 g，每日2次）。 最终完成研究获得完整数据资料的患者77例，其中HAART组42例、扶正抗毒丸组35例，疗程均为12个月。观察HAART联合扶正抗毒丸对气虚质无症状期HIV感染者CD4+、CD4+CD28+、CD8+、CD8+CD28+、CD8+CD38+、CD8+HLA-DR+T细胞绝对计数及HIV-RNA的作用。结果?与本组治疗前比较，两组患者CD4+CD28+T细胞绝对计数升高（Z=-2.363，-4.406，P<0.05，P<0.01），HIV-RNA<100 copy/mL所占百分比均增加（χ2=72.593，62.279，P<0.01）。HAART组CD8+、CD8+CD28+、CD8+HLA-DR+T细胞绝对计数均显著降低（Z=-2.788，-4.395，-2.369，P<0.05，P<0.01），扶正抗毒丸组CD8+、CD8+HLA-DR+T细胞绝对计数均显著降低（Z=-3.276，-2.334，P<0.05，P<0.01）。治疗后，与HARRT组比较，扶正抗毒丸组CD4+CD28+T、CD8+CD28+T细胞绝对计数显著升高（Z=-3.437，-1.969，P<0.01，P<0.05）。HAART组不良事件发生率9.52% （4/42） 与扶正抗毒丸组的5.71% （2/35） 比较差异无统计学意义（χ2=0.038，P=0.846）。结论?HAART联合扶正抗毒丸能有效增加CD4+CD28+T和稳定CD8+CD28+T细胞绝对计数，且安全性高。     

Clinical Evaluation on Xiyanping Injection in the Treatment of Bronchopneumonia in Children Based on Meta‑Analysis

Objective: The aim of this study is to evaluate the effectiveness and safety of xiyanping injection (XYPI) in the treatment of children with bronchopneumonia. Methods:Asystematic and comprehensive search was conducted in the domestic and foreign electronic databases CNKI, SinoMed, VIP, WanFang DATA, PubMed, The Cochrane Library, Embase, Web of Science, Clinical?Trials.gov, and the search date ended on May 30, 2019. Inclusion criteria: (1) the types of studies included were randomized controlled trials; (2) the study participants were infants and children with a clear diagnosis of bronchopneumonia, without gender and ethnic restrictions; (3) the intervention test group was XYPI or the control group plus XYPI. The control group was routine treatment (RT) (basic treatment such as fever, cough and asthma, oxygen inhalation, anti?infection, maintaining water, electrolyte balance, etc.) or other Western medicine or RT + other Western medicine treatment. Except for XYPI, the two groups were consistent in intervention measures.According to the Cochrane Handbook, 5.1 evaluation standard and a meta?analysis of the final included studies was performed using RevMan 5.3 software. Results:Atotal of 57 studies were included, with a total sample size of 8454 cases, of which 4255 were in the experimental group and 4199 were in the control group. Meta?analysis results showed that (1) Total effective rate: XYPI group was better than the control group (relative risk [RRRT] = 1.25, 95% confidence interval [CI] [1.15, 1.36], P < 0.00001; RRRT + RBVI = 1.18, 95% CI [1.09, 1.29], P < 0.0001; RR antibiotic = 1.16, 95% CI [1.09, 1.24], P < 0.00001, RRRT + antibiotic = 1.22, 95% CI [1.16, 1.27], P < 0.00001); antipyretic time: XYPI group was better than the control group (mean difference [MDRT] = ?0.97, 95% CI [?1.17, ?0.76], P < 0.00001; MDRT + antibiotic = ?2.28, 95% CI [?2.88, ?1.67], P < 0.00001; MDRT + RBVI = ?1.51, 95% CI [?1.81, ?1.21], P < 0.00001; cough disappearing time: XYPI group was better than the control group (MDRT = ?1.37, 95% CI [?1.74, ?1.00], P < 0.00001; MDRT + antibiotic = ?1.71, 95% CI [?2.04, ?1.37], P < 0.00001; MDRT + RBVI = ?1.51, 95% CI [?2.15, ?0.86], P < 0.00001); disappearance time of lung rales: XYPI group was better than the control group (MDRT = ?1.11, 95% CI [?1.35, ?0.88], P < 0.00001; MDRT + RBVI = ?1.63, 95% CI [?2.23, ?1.03], P < 0.00001). The difference was statistically significant; (2) Of the 57 studies (a total of 8454 cases), 29 studies reported adverse reactions, of which 18 studies did not find adverse reactions, and 11 studies reported adverse reactions such as nausea, vomiting, and rash after medication in both groups. (3) The funnel chart indicated potential publication bias. Conclusion: Based on the existing clinical evidence, XYPI can have a certain effect on the treatment of children with bronchopneumonia, and it is not yet possible to conclude its safety evaluation. Moreover, due to the low quality of the included studies, this evidence is still used with cautious clinically.     

Journal of Acupuncture and Tuina Science Instructions for Authors

正The Journal of Acupuncture and Tuina Science,a peerreview journal with an international scope(ISSN 1672-3597,CN 31-1908/R,Bimonthly),is embodied by‘Springer Verlag’Database,Index of Copernicus(IC)and Chinese Scientific and Technical Paper and Citations Data(CSTPCD).You can search full text on http://www.springerlink.com/content/1672-3597,http://epub.cnki.net/kns/oldnavi/n_item.aspx?naviid=100base id=zjtnnavilink=journal+of+acupuncture+and+tuina+science,     

基于颜色变化的麸炒山药质量标准及炮制工艺探究

目的基于颜色变化探究麸炒山药质量标准及炮制工艺。方法利用色差仪测定生山药及不同炮制程度的麸炒山药饮片外观色度值L^?、a^?、b^?值(L^?为亮度,a^?为红绿色度值,b^?为黄蓝色度值),求其色度值双侧90%参考范围,并采用主成分分析对色度值进行聚类分析,结合SPSS 21.0软件,建立L^?、a^?、b^?与T(炮制温度)、t(炮制时间)的非标准化典则判别函数式。利用红外光谱技术分析生山药、不同炮制程度麸炒山药中相关化学基团的变化。结果麸炒山药炮制适中品色度值范围是47.20≤E^?ab<48.71,基于色度值的炮制工艺参数非标准化典则判别函数式分别为L^?=-0.014T+0.57t+50.517、a^?=0.295t+0.025;b^?=0.023T+1.845。山药麸炒后,红外共轭效应增强。结论色差仪可以实现不同炮制程度麸炒山药饮片外观颜色的客观化评判,基于色度值建立的非标准化典则判别函数式可为中药炮制工艺的规范化提供科学依据。     

Journal of Acupuncture and Tuina Science Instructions for Authors

正The Journal of Acupuncture and Tuina Science,a peerreview journal with an international scope(ISSN 1672-3597,CN 31-1908/R,Bimonthly),is embodied by‘Springer Verlag’Database,Index of Copernicus(IC)and Chinese Scientific and Technical Paper and Citations Data(CSTPCD).You can search full text on http://www.springerlink.com/content/1672-3597,http://epub.cnki.net/kns/oldnavi/n_item.aspx?naviid=100base id=zjtnnavilink=journal+of+acupuncture+and+tuina+science,and http://c.wanfangdata.com.cn/periodical-zjtnyx-e.aspx.     

指导学生掌握中医药学习记忆方法

1公式记忆 学生反映中医难学,太灵活,无规律可寻,无公式可用.在辨证的教学中我尽量将教学内容归纳为公式:如表证=肌表证+肺系证,阳虚=气虚+虚寒,阴虚=血虚+虚热.卫分证=初期+表热,气分证=二期+热盛,营分证=三期+神昏,血分证=晚期+动血+动风.白喉辨证风热疫毒证=风热+点状假膜,阴虚燥热=嘶吠+条状假膜,疫毒攻喉=嘶吠+梗阻.这样学生有规律可寻,有公式可用,可以纲举目张,从而大大提高记忆效率.     

高效液相色谱法测定地黄中梓醇的含量

 本文采用高效液相色谱法测定地黄中梓醇的含量?以 KYWG-C18为固定相,0.6%乙腈为流动相,UV检测波长为210nm,梓醇进样量在2~10μg与峰面积呈直线相关(r=0.9999;回归方程Y=0.0007158+0. 00004318X)?平均回收率为 99. 00%,RSD为 3. 38%(n=6)?并用该方法对河南产 16批鲜地黄和生地黄样品进行了梓醇含量测定?     

川芎嗪调控miR⁃31⁃5p/Ednrb通路抑制人肺泡上皮细胞BEAS⁃2B凋亡和炎症反应

目的探讨川芎嗪(TMP)调控miR?31?5p/内皮素受体B(Ednrb)通路对人肺泡上皮细胞BEAS?2B凋亡和炎症反应的影响。方法采用1μg/mL脂多糖(LPS)处理BEAS?2B细胞构建炎症模型。将BEAS?2B细胞分为对照组、LPS组、LPS+川芎嗪5μmol/L组、LPS+川芎嗪20μmol/L组、LPS+川芎嗪80μmol/L组、LPS+miR?con组、LPS+miR?31?5p组、LPS+si?con组、LPS+si?Ednrb组、LPS+川芎嗪+pcDNA组、LPS+川芎嗪+pcDNA?Ednrb组。酶连免疫吸附实验(ELISA)试剂盒检测细胞培养液中白介素IL?1β、IL?6和TNF?α(肿瘤坏死因子)的含量;RT?qPCR和Western blot检测miR?31?5p(炎性相关微小RNA)和Ednrb(内皮素受体B)表达。双荧光素酶报告实验和Western blot验证miR?31?5p对Ednrb的靶向调控关系。结果与对照组比较,LPS组BEAS?2B细胞Ednrb蛋白、凋亡率以及IL?1β、IL?6和TNF?α的水平增加,miR?31?5p表达降低(P<0.01);与LPS组比较,LPS+川芎嗪5μmol/L组、LPS+川芎嗪20μmol/L组、LPS+川芎嗪80μmol/L组BEAS?2B细胞Ednrb蛋白表达、凋亡率以及IL?1β、IL?6和TNF?α的水平降低,miR?31?5p表达升高(P<0.05,P<0.01)。miR?31?5p靶向负性调控Ednrb表达。与LPS+miR?con组比较,LPS+miR?31?5p组BEAS?2B细胞凋亡率以及IL?1β、IL?6和TNF?α的水平降低(P<0.01);与LPS+si?con组比较、LPS+si?Ednrb组BEAS?2B细胞凋亡率以及培养液中IL?1β、IL?6和TNF?α的水平降低(P<0.01);与LPS+川芎嗪+pcDNA组比较,LPS+川芎嗪+pcDNA?Ednrb组BEAS?2B细胞凋亡率、培养液中IL?1β、IL?6和TNF?α的浓度升高(P<0.05)。结论川芎嗪通过上调miR?31?5p/Ednrb通路抑制人肺泡上皮细胞BEAS?2B凋亡和炎症反应。     

射干鸢尾的核型分析

 目的：对射干鸢尾染色体数目、形态等进行研究，为该种鉴定、演化和良种选育等提供必要的细胞学资料。方法：采用常规制片方法，结合显微摄影对染色体进行检测分析。结果：染色体数目为2n=40。核型公式为K(2n)=40=30m+6sm+2st(2SAT)+2T，染色体相对长度组成为2n=40=2L+14M₂+22M₁+2S，属于2A型。全组染色体总长74.16μm，长臂总长4492μm，核型不对称系数60.57%?染色体组总体积153.17μm³。结论：射干鸢尾染色体数目、形态清晰，可为进一步的深入研究打下基础。     

UPLC-QTOF-MS法探讨温肾清毒方对大鼠生殖器官中依非韦伦浓度的影响

目的?探索温肾清毒方“艾可清”对大鼠生殖器官中依非韦伦浓度（EFV）的影响。方法?24只雄性SD大鼠随机分为4组， EFV+高剂量艾可清组、EFV+低剂量艾可清组、EFV组及空白组，每组6只。大鼠灌胃给药7天后处死；腹腔静脉采血，取上清液；取前列腺、睾丸、附睾、膀胱组织，按组织和4 ℃双蒸水1：2比例配置匀浆液。超高效液相色谱四极杆飞行时间质谱分析（UHPLC-QTOF/MS） 检测血清和匀浆中EFV响应浓度。结果?空白组无离子响应。EFV组、EFV+高剂量组、EFV+低剂量组各组内血浆和组织中离子响应浓度比较差异无统计学意义（均P>0.05）；3个组的血浆的EFV浓度比较差异无统计学意义（P>0.05），但是EFV+高剂量艾可清组及EFV+低剂量艾可清组组织中EFV浓度高于EFV组（P=0.018）。各组组织和血浆中EFV的分布如下：EFV+低剂量组> EFV+高剂量组>EFV组。结论?艾可清能够提高大鼠生殖器官组织中EFV浓度。     

HPLC测定黄柏石膏散中盐酸巴马丁和盐酸小檗碱含量

 目的 建立测定黄柏石膏散中盐酸巴马丁和盐酸小檗碱含量的高效液相色谱法。方法 色谱柱：MZ C₁₈柱(4.6mm×250mm,5μm);流动相：水-乙腈(71:29)，含0.5%三乙胺、磷酸调pH至3.0;检测波长343 nm;流速：1 mL·min^-1。结果 盐酸巴马丁和盐酸小檗碱的理论板数分别为6 500和7500。盐酸巴马丁回归方程为7=-433 601+93 680 500×,r= 0.9999,线性范围0.1674?0.837 2μg，平均回收率为98.7% (n=5，RSD 1.3%)。盐酸小檗碱回归方程为Y=-887 699+95 231 971X,r=0.999 9，线性范围0.378 9?1.894μg，平均回收率为99.2%(n=5，RSD1.6%)。结论 该法操作简便,结果准确，可用于黄柏石青散中盐酸巴马丁和盐酸小檗碱含量测定。     

热敏灸、隔姜灸治疗周围性面瘫临床疗效的系统评价

目的:采用系统评价热敏灸、隔姜灸治疗周围性面瘫的临床疗效,为临床治疗该病提供直观、准确、科学的指导方案。方法:采用电子检索国内外大型数据库及手工检索国内重要核心杂志医学杂志,筛选出合格文献,对纳入的文献进行质量评估,采用Rev Man5.3.4进行统计学分析。结果:共纳入17篇临床随机对照试验,共1429例。Meta分析结果显示:(1)有效率:中药+热敏灸VS中药+针刺,差异具有统计学意义(RR=1.24,95%CI[1.03,1.50],Z=2.30,P=0.02);热敏灸+针刺VS传统悬灸+针刺,差异具有统计学意义(RR=1.17,95%CI[1.02,1.33],Z=2.24,P=0.03);隔姜灸+针刺VS针刺,差异具有统计学意义(RR=1.24,95%CI[1.02,1.51],Z=2.14,P=0.03)。(2)显愈率:热敏灸+针刺VS针刺,差异具有统计学意义(RR=1.17,95%CI[1.07,1.27],Z=3.49,P=0.0005);热敏灸VS针刺,差异具有统计学意义(RR=1.91,95%CI[1.19,3.07],Z=2.67,P=0.008)。(3)面神经功能评价:热敏灸+针刺VS针刺,差异具有统计学意义(WMD=7.15,95%CI[4.64,9.65],Z=5.59,P0.00001);热敏灸+针刺VS传统悬灸+针刺,差异具有统计学意义(WMD=6.29,95%CI[4.10,8.48],Z=5.62,P0.00001);隔姜灸+针刺VS针刺,差异具有统计学意义(WMD=3.40,95%CI[1.88,4.92],Z=4.38,P0.0001)结论:热敏灸、隔姜灸与其对照组相比,治疗周围性面瘫可能有一定的临床疗效优势,但需更多高质量研究进一步证实。     

碳纤维电极溶出伏安法同时测定丹参中锌和镉

目的：用自制碳纤维电极,采用线性扫描溶出伏安法实现锌、镉同时在碳纤维电极上的检测。方法：考察了电解质底液、富集电位、富集时间及扫描速度对Zn²⁺、Cd²⁺溶出伏安行为的影响。结果：在1 mol?L^-1硫酸介质中,Zn²⁺、Cd²⁺分别在-0.97 V和-0.77 V附近产生灵敏的阳极溶出峰,峰电流与浓度呈良好的线性相关,相关系数R²分别为0.996 5和0.995 4。锌、镉的检出限（S/N=3）分别为1.5×10^-9 mol?L^-1和1.0×10^-10 mol?L^-1, 平均加标回收率分别为98.9%和98.1%,相对标准偏差（n=6）分别为2.72%和2.45%。结论：用碳纤维电极同时检测Zn²⁺和Cd²⁺的方法具有简便、灵敏和准确的特点。     

胡芦巴与王不留行的染色体研究

本文对胡芦巴和王不留行的染色体核型进行了分析．其染色体数目分别为2n=16和2n=30;其核型分别为K＝2n=16=16sm(2SAT)和K=2n=30=4M+10m+16sm(4SAT)     

针刺治疗脑卒中后抑郁：随机对照研究

【摘要】目的：探讨针刺治疗脑卒中后抑郁的疗效和安全性。方法：采用随机双盲对照设计,将符合DSM-IV目前重性抑郁发作诊断标准的43例脑卒中患者简单随机分入实验组（针刺+安慰剂）组和对照组（安慰针刺+氟西汀）;依次于治疗前、第1、2、4、6周末双盲法用Hamilton抑郁量表、Asberg抗抑郁药副作用量表和自编针刺不良反应清单进行疗效和安全性评价。结果：治疗第6周末,实验组和对照组有效率分别为73.9%（17/23）和80.0%（16/20）,疗效差异无统计学意义（?2=0.222,P=0.637）;重复测量方差分析显示实验组的Asberg抗抑郁药副作用评分显著低于对照组（F=5.19,P=0.01）;两组针刺不良反应发生率分别为13.0%（3/23）和15.0%（3/20）,差异无统计学意义（?2=0.034,P=0.853）。结论：针刺疗法治疗脑卒中后抑郁的疗效与氟西汀相当,没有明显药物治疗引起的副作用。 【关键词】 针刺;氟西汀;脑卒中后抑郁;随机对照研究     

HPLC-ELSD法同时测定小鼠股骨中钙和磷

目的:建立一种同时测定小鼠股骨中钙和磷含量的方法。方法:以反相高效液相色谱-蒸发光散射检测器(HPLCELSD)法,采用Prevail C18色谱柱(250 mm×4.6 mm i.d.,5?m),以乙腈与0.7%三氟醋酸溶液(含5.0 mmol/L)为流动相进行洗脱,洗脱时间为10 min。结果:氯化钙、磷酸峰面积的自然对数与相应浓度的自然对数呈良好的线性关系,其方程为氯化钙:Y=1.206 0X+8.445 8,r=0.999 8,线性范围0.10⁰.30 mg/ml,磷酸:Y=1.428 9X+9.074 0,r=0.999 7,线性范围0.0270.30 mg/ml,磷酸:Y=1.428 9X+9.074 0,r=0.999 7,线性范围0.027⁰.081 mg/ml。氯化钙、磷酸平均回收率分别为100.5%,97.9%,RSD分别为1.8%,2.3%。结论:该法快速、简便、准确,对判断和研究骨矿物质的含量多有重要的意义。     

Bioactivities and Pharmaceutical Effects of 1-Aminocyclopro- panecarboxylic Acid

作 者：

ZHU Qin-wei    KRAEMER Alexander    ZHU Xu-xiang  

作者单位：

Faculty of Public Health,Bielefeld University,Bielefeld 33615,Germany 

期 刊：

中草药（英文版）    

Journal：

CHINESE HERBAL MEDICINES  

年,卷(期)：

2010, 02(2) 

分类号：

R2 

Keywords：

1-aminocyclopropanecarboxylic acid    bioactivities    cerebro- and cardiovascular    neurological protection    non-protein acid    pharmaceutical effects   

机标分类号：

R96 R97 

机标关键词：

neuroprotective effectscardiovascular systemlearning and memorydetermination ofclinical trialsstudiesnervous systemsignificanceamino acidglutamatedifferentcountriesAbstractsresearcharticlesvarietyResultsnaturalMedlinemedical 

基金项目：

 

DOI：

10.3969/j.issn.1674-6384.2010.02.001 

参考文献(98条)

1. Ethylene in Plant Biology 1973
2. Ethylene biosynthesis:Identification of 1-aminocyclopropane-1-carboxylic acid as an intermediate in the conversion of methionine to ethylene 1979(1)
3. A clinical trial of the effects of dietary patterns on blood pressure 1997
4. Rat middle cerebral artery occlusion:Evaluation of the model and development of a neurologic examination 1986(3)
5. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures 1993
6. Lipid peroxidation forms ethylene from 1-aminocyclopropane-1-carboxylic acid and may operate in leaf senescence 1984
7. Chronic administration of a glycine partial agonist alters the expression of N-methyl-D-aspartate receptor subunit mRNAs 1997(3)
8. Protection from hypoxic injury in cultured hepatocytes by glycine,alanine,and serine 1994
9. 1-Aminocyclopropane-1-carboxylic acid:A new amino-acid in perry pears and cider apples 1957(4555)
10. The free amino acid of certain British fruits 1960
11. Buffer GW.Peterson PJ Uptake and metabolism of inorganic forms of seleniurn-75 by Spirodela oligorrhiza 1967
12. Cameron AC.Fenton CAL.Yu Y.Adams DO Yang SF Increased production of ethylene by plant tissues treated with 1-aminocyclopropane-1-carboxylic acid 1979(2)
13. Castro-Puyana M.Crego AL.Marina ML.Garcia-Ruiz C CE methods for the determination of non-protein amino acids in foods 2007(22)
14. Cherkofsky SC 1-aminocyclopropanecarboxylic acid:Mouse to man interspecies pharmacokinetic comparisons and allometric relationships 1995(10)
15. Choi DW Glutamate neurotoxicity and diseases of the nervous system 1988(8)
16. Cowie DB.Cohen GN Biosynthesis by Escherichia coli of active altered proteins containing selenium instead of sulfur 1957(2)
17. DeGraba TJ.Pettigrew LC Why do neuroproteetive drugs work in animals but not humans 2000(2)
18. Ding CM.Zhu XX.Zhang ZM Test report of ACPC feeding table poultry 2004(2)
19. Dirnagl U.Iadecola C.Moskowitz MA Pathobiology of ischaemic stroke:An integrated view 1999(9)
20. Elliott P.Stamler J.Dyer AR.Appel L,Dennis B,Kesteloot H,Ueshima H,Okayama A,Chart Q,Garside DB,Zhou B Association between protein intake and blood pressure:The INTERMAP Study 2006(1)
21. Faden AI.Jacobs TP Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate mechanism 1984
22. Fleisch JM M(O)glichkeiten der Blutdrucksenkung dutch operantes Konditionieren unter Einsatz einer neuen BiofeedbackAnordnung 1996
23. Fossom LH.Basile AS.Skolnick P Sustained exposure to 1-aminocyclopropanecarboxylic acid,a glycine partial agonist,alters N-methyl-D-aspartate receptor function and subunit composition 1995(6)
24. Fossom LH.Von Lubitz DK.Lin RC.Skolnick P Neuroprotective actions of 1-aminocyclopropanecarboxylic acid(ACPC):A partial agonist at strychnine-insensitive glycine sites 1995(4)
25. Gao M.Kondo F.Murakami T.Xu JW,Ma N,Zhu XX,Mod K,Ishida T 1-Aminocyclopropanecarboxylic acid,an antagonist of N-methyl-D-aspartate receptors,causes hypotensive and antioxidant effects with upregulation of heme oxygenase-1 in stroke-prone spontaneously hypertensive rots 2007(3)
26. Grant KA.Valverius P.Hudspith M.Tabakoff B Ethanol withdrawal seizures and the NMDA receptor complex 1990(3)
27. Haque MM.Nasreen SA Epidemiological study of risk factors of stroke and its immediate consequence 2008(2)
28. Herman BH.Goldstein A Antinoeiception and paralysis induced by intrathecal dynorphin A 1985(1)
29. Heyman S.Spokes K.Rosen S.Epstein FH Mechanism of glycine protection in hypoxic injury:Anologies with glycine receptor 1992(1)
30. Howell SE.Miller SR.McCallister JD.Cherkofsky SC Patrick KS Gas chromatographic-mass spectrometric determination of urinary 1-aminocyclopropanecarboxylic acid in mice using a deuterated internal standard 1995(1)
31. Jia M.Dong Z.Zhu Y.Guan YB Molecular targets of Chinese used in treatment of stroke 2006(12)
32. Kolesnikov YA.Maccechini ML.Pastemak GW 1-Aminocyclopropane carboxylic acid(ACPC)prevents mu and delta opioid tolerance 1994(18)
33. Kunz C.Linn T.Gortner L.Bretzel RG Ern(a)hrungsprobleme bei Kindern und Erwachsenen 2003
34. Layer RT.Bland LR.Skolnick P MK-801,but not drugs acting at strychnine-insensitive glycine receptors,attenuate methamphetamine nigrostriatal toxicity 1993(1)
35. Lea PJ.Norris RD The use of amino acid analogues in studies of plant metabolism 1976
36. Levy SB Multidrug resistance-a sign of the times 1998(19)
37. Liang ZH.Wei EQ.Zhu CY.Zhang SH,Xu HM An improved imaging analysis for quantitative 2003(6)
38. Lin JC.Tsao WL.Wang Y Cardiovascular effects of NMDA in the RVLM of spontaneously hypertensive rats 1995(3)
39. Lin Y.Fossom LH.Skolnick P.Long JB Sustained exposure to a glycine receptor partial agonist differentially alters NMDA receptor agonist and antagonist potencies in cultured spinal cord neurons 1998
40. Long JB.Petras JM.Mobley WC.Holaday JW Neurological dysfunction after intrathecal injection of dynorphin A(1-13)in the rat.Ⅱ.Non-opioid mechanisms mediate loss of motor,sensory,and autonomic function 1988(3)
41. Long JB.Rigamonti DD.Oleshansky MA.Wingfield CP Martinez-Arizala A Dynorphin A-reduced rat spinal cord.injury:Evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury 1994(1)
42. Long JB.Skolnick P 1-Aminocyclopropanecarboxylic acid protects against dynorphin A-induced spinal injury 1994(3)
43. Longa EZ.Weinstein PR.Carlson S.Cummins R Reversible middle cerebral artery occlusion without craniectomy in rats 1989(1)
44. Lopes T.Neubauer P.Boje KM Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test 1997(4)
45. Lundy EF.Solik BS.Frank RS.Lacy PS Combs DJ Zelenock GB D'Alecy LG Morphometric evaluation of brain infarcts in rats and gerbils 1986(3)
46. Lürssen K.Naumann K.Schrt(o)der R 1-Aminocyclopropane-1-carboxylic acid-An intermediate of ethylene biosynthesis in higher plants 1979
47. MacMahon S.Peto R.Cutler J.Collins R,Sofrlie P,Neaton J,Abbott R,Godwin J,Dye Blood pressure,stroke and coronary heart disease.Part 1:Prolonged differences in blood pressure.Prospective observational studies corrected for the regression dilution bias 1990
48. Manev H.Costa E.Wroblewski JT.Guidotti A Abusive stimulation of excitatory amino acid receptors:A strategy to limit neurotoxicity 1990(10)
49. Marvizón JC.Lewin AH.Skolnick P 1-Aminocyclopropane carboxylic acid:A potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex 1989(3)
50. Meyer BU.Schneider W.Elstner EF Peroxide-dependent amino acid oxidation and chemiluminescence catalysed by magnesium-pyridoxal phosphate-glutamate complex 1992(3)
51. Mills E.Minson J.Drolet G.Chalmers J Effect of intrathecal amino acid receptor antagonists on basal blood pressure and pressor responses to brainstem stimulation in normotensive and hypertensive rats 1990(6)
52. Muir KW.Lees KR Clinical experience with excitatory amino acid antagonist drugs 1995(3)
53. Nagasawa H Effect of ACC,a component of Coprinus comafus,on fertility of male mice 1995
54. Nahum-Levy R.Fossom LH.Skolnick P.Benveniste M Putative partial agonist 1-aminocyclopropanecarboxylic acid acts concurrently as a glycine-site agonist and a glutamate-site antagonist at N-methyl-D-aspartate receptors 1999(6)
55. Nowak G.Li Y.Paul IA Chronic glycine treatment desensitizes the behavioral response to 1-aminocyclopropanecarboxylic acid(ACPC),a partial agonist at the strychnine-insensitive glycine site of the NMDA receptor complex 2000(2)
56. Olney JW.Labruyere J.Wang G.Wozniak DF Price MT Sesma MA NMDA antagonist neurotoxicity:Mechanism and prevention 1991(5037)
57. Papp M.Gruca P.Willner P Selective blockade of druginduced place preference conditioning by ACPC,a functional NDMA-receptor antagonist 2002(5)
58. Papp M.Moryl E Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression 1996(2-3)
59. Patat A.Molinier P.Hergueta T.Brohier S,Zieleniuk I,Danjou P,Warot D,Puech A Lack of amnestic,psychotomimetic or impairing effect on psychomotor performance of eliprodil,a new NMDA antagonist 1994(3)
60. Peterson SL Infusion of NMDA antagonists into the nucleus reticularis pontis oralis inhibits the maximal electroshock seizure response 1995(1-2)
61. Peterson SL.Purvis RS.Griffith JW Differential neuroprotective effects of the NMDA receptor-associated glycine site partial agonists l-aminocyclopropanecarboxylic acid(ACPC)and D-cycloserine in lithium-pilocarpine status epilepticus 2004(5)
62. Popik P.Rygielaka Z A partial agonist at strychnine-insensitive glycine sites facilitates spatial learning in aged rats 1999(1)
63. Priestley T.Home AL.McKeman RM.Kemp JA The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures 1990(1-2)
64. Przegali(n)ski E.Tatarczy(n)ska E.Dere(n)-Wesolek A.ChojnackaWójcik E Anticonfiict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors 1996(1)
65. Przegali(n)ski E.Tatarczy(n)ska E.Dere(n)-Wesolek A.ChojnackaWojcik E Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist 1997(1)
66. Przegali(n)ski E.Tatarczy(n)ska E.Klodzi(n)ska A.Chojnacka-Wójcik E Tolerance to anxiolytic-and antidepressant-like effects of a partial agonist of glycineB receptors 1999(3)
67. Rogawski MA Low affinity channel blocking(uncompatitive)NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability 2000(1)
68. Rubenstein E Methods for the use of nonprotein amino acids as therapeutic agents 2001
69. Schneider W Der hypocholesterin(a)mische und antiatherosklerotische EinfluB yon Magnesium-Pyridoxal-5'-phosphatGlutamat im Serum,in der Leber und der Aorta hypercholesterin(a)mischer Ratten und Kaninchen" 1987
70. Schroeder R.Luerssen K Mittel zur Regulierung des Pflanzenwachstums 1980
71. Simberkoff MS Drug-resistant pneumococcal infections in the United States.A problem for clinicians,laboratories,and public health 1994(23)
72. Skolnick P.Marvizón JC.Jackson BW.Monn JA Rice KC Lewin AH Blockade of N-methyl-D-aspartate induced convulsions by 1-aminocyclopropanecarboxylates 1989(18)
73. Skolnick P.Miller R.Young A.Boje K,Trullas R Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methylD-aspartate receptor complex 1992(4)
74. Stevens CW.Yaksh TL Dynorphin A and related peptides administered intrathecally in the rat:A search for putative kappa opiate receptor activity 1986(3)
75. Stromberg MF.Volpicelli JR.O'Brien CP.Mackler SA The NMDA receptor partial agonist,1-aminocyclopropanecarboxylic acid(ACPC),reduces ethanol consumption in the rat 1999(3)
76. Swain T Secondary compounds as protective agents 1977
77. Trullas R.Folio T.Young A.Miller R,Boje K,Skolnick P 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models 1991(3)
78. Trullas R.Skolnick P Functional antagonists at the NMDA receptor complex exhibit antidepressant actions 1990(1)
79. V(a)h(a)talo ML.Virtanen AI Cyclic α-aminocarboxylic acid in berries ofcowberry 1957
80. Viu E.Zapata A.Capdevila J.Skolnick P,Trullas R Glycine(B)receptor antagonists and partial agonists prevent memory deficits in inhibitory avoidance learning 2000(2)
81. Von Lubitz DK.Lin RC.McKenzie RJ.Devlin TM McCabe RT Skolnick P A novel treatment of global cerebral ischemia with a glycine partial agonist 1992(1)
82. Wang FR.Jiang YS.Xiao WW.Zhang SM Mice focal cerebral ischemia-reperfusion model established by internal carotid artery suture method 2003(2)
83. Weinberg JM.Venkatachalam MA.Roeser NF.Davis JA Varani J Johnson KJ Amino acid protection of cultured kidney tubule cells against calcium ionophore-induced lethal cell injury 1991(6)
84. Yang SF The formation of ethylene from l-aminocyclopropane-l-carboxylic acid 1984
85. Yang SF A bit in the research on ethylene biosynthesis 1998
86. Yang SF.Hoffman NE Ethylene biosynthesis and its regulation in higher plants 1984
87. Yao JF.Zhang ZM.Xu GP.Xu FQ,Zhou HC,Wang XH,Deng B Feeding test report of ACC on poultry 2001
88. Ye CL.Li BH Protective effects of clonidine on cerebral ischemia in mice and cats 1993(1)
89. Yu YB.Adams DO.Yang SF l-Aminocyclopropanecarboxylate Synthase,a Key Enzyme in Ethylene Biosynthesis 1979(1)
90. Zapata A.Capdevila JL.Viu E.Tmllas R 1-Aminocyclopropane-carboxylic acid reduces NMDA-induced hippocampal neurodegeneration in vivo 1996(2)
91. Zhang J.Xu JL.Zhu XX Nonprotein amino acid ACC regulates and controls the growing development of silkworm 1990(4)
92. Zhao ZR Protection of ACC on brain neurological impairment induced by ischemia 2005
93. Zhao ZR.Zhu QW.Zhu XX Protection of 1-aminocyclopropanecarboxylic acid against brain neurological impairment by ischemia 2005(10)
94. Zhu XX The Regulating Effects of ACC on the Rice.Advances in plant growth substance and herbicide research and application(1) 1998
95. Zhu XX New feed additive ACPC.New Feed Certificate No.[2003]02 2003
96. Zhu XX 1-Aminocylopropanecarboxylic Acid(ACC)on Cardiocerebrovascular Diseases 2005(26)
97. Zhu XX Application of ACPC in preparation of medicine against cardiovascular diseases 2007
98. Zhu XX.Xu JL Physiological actions of nonprotein amino acid ACC of animals 1991(4)

>>更多...     

Effect of Yangxinshi Tablets on the Phenotype and Function of Monocytes in Patients with Unstable Angina Pectoris of Coronary Heart Disease

Objective: The objective of this study was to observe the effect of Yangxinshi tablets on the phenotype and function of peripheral blood monocytesin patients with unstable angina of coronary heart disease (CHD) and to explore the possible mechanism of Yangxinshi tabletsin the treatment of CHD. Methods: A total of 100 patients with unstable angina of CHD were randomly divided into two groups: GroupA– treatment group and Group B – control group. The phenotypic and functional changesin blood monocytes and the changesin serum inflammatory factors before and after treatment were compared in the two groups. Results: The expression of CD14+ CD163+ interleukin (IL)?10+ was significantly higher in the control group than in the patients with unstable angina of CHD, whereas the expression of CD14+ CD163? IL?12+ was lower. The concentration of IL?10 was higher in the control group than in the patients with unstable angina, whereas the concentration of tumor necrosis factor-α (TNF?α) and IL?12 wassignificantly lower. In GroupA, the expression of CD14+ CD163+, CD14+ CD206+, and CD14+ CD163+ CD206+ in peripheral blood monocytes increased after treatment than before treatment, whereas the expression of CD14+ CD163? CD206? decreased. The expression of CD14+ CD163? IL?12+ decreased after treatment than before, whereas CD14+ CD163+ IL?10+ expression increased. The serum concentration of IL?10 in Group A was higher after treatment than before, whereas that of IL?12 and TNF?α was lower. In Group B, the phenotype and function of the peripheral blood monocytes remained unchanged. Conclusion: Yangxinshi tablet therapy can change the phenotype of the peripheral blood monocytes in patients with unstable angina of CHD. Yangxinshi tablet therapy changes the inflammatory state in patients with an increase in the expression of anti?inflammatory factors and a decrease in the expression of inflammatory factors.     

刺萼参的染色体组型分析

本文报道刺萼参体细胞染色体数目2n=16,核型公式K(2n)=16=14m+2Sm,染色体相对长度组成为2n=16=10M2+6M1,核型不对称系数AS